Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter McLaughlin

Showing results (101-110 of 116) with videos related to

Pageof 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2005
Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomasIssa F Khouri, Rima M Saliba, Chitra Hosing, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 2, 2013
Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trialJason R Westin, Michael A Thompson, Vince D Cataldo, et al.
British Journal of Haematology|July 23, 2016
Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic modelYiming Chen, Sattva Neelapu, Lei Feng, et al.
British Journal of Haematology|August 12, 2015
Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphomaDai Chihara, Barbara Pro, Sanam Loghavi, et al.
Blood|February 29, 2012
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphomaAnas Younes, Yasuhiro Oki, Peter McLaughlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2005
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabineJorge E Romaguera, Luis Fayad, Maria A Rodriguez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2002
CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcomeGeorge Z Rassidakis, L Jeffrey Medeiros, Simonetta Viviani, et al.
Blood|April 16, 2008
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximabIssa F Khouri, Peter McLaughlin, Rima M Saliba, et al.
Plos One|March 21, 2015
Nontypeable Haemophilus influenzae induces sustained lung oxidative stress and protease expressionPaul T King, Roleen Sharma, Kim O'Sullivan, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 3, 2014
Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trialYasuhiro Oki, Michael S Ewer, Daniel J Lenihan, et al.
Pageof 12

Showing results (101-110 of 116) with videos related to

Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2005
Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomasIssa F Khouri, Rima M Saliba, Chitra Hosing, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 2, 2013
Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trialJason R Westin, Michael A Thompson, Vince D Cataldo, et al.
British Journal of Haematology|July 23, 2016
Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic modelYiming Chen, Sattva Neelapu, Lei Feng, et al.
British Journal of Haematology|August 12, 2015
Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphomaDai Chihara, Barbara Pro, Sanam Loghavi, et al.
Blood|February 29, 2012
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphomaAnas Younes, Yasuhiro Oki, Peter McLaughlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2005
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabineJorge E Romaguera, Luis Fayad, Maria A Rodriguez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2002
CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcomeGeorge Z Rassidakis, L Jeffrey Medeiros, Simonetta Viviani, et al.
Blood|April 16, 2008
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximabIssa F Khouri, Peter McLaughlin, Rima M Saliba, et al.
Plos One|March 21, 2015
Nontypeable Haemophilus influenzae induces sustained lung oxidative stress and protease expressionPaul T King, Roleen Sharma, Kim O'Sullivan, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 3, 2014
Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trialYasuhiro Oki, Michael S Ewer, Daniel J Lenihan, et al.
Pageof 12